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O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked 
β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or 
removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine 
residues of nucleocytosolic and mitochondrial proteins, respectively. The perturbed 
homeostasis of O-GlcNAc cycling results in several pathological conditions. Human OGA is 
a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are 
experienced, such as tauopathy in Alzheimer's disease. A new class of potent OGA inhibitors, 
2-acetamido-2-deoxy-D-glucono-1,5-lactone (thio)semicarbazones, have been identified. 
Eight inhibitors were designed and synthesized in five steps starting from D-glucosamine and 
with 15-55 % overall yields. A heterologous OGA expression protocol with strain selection 
and isolation has been optimized that resulted in stable, active and full length human OGA 
(hOGA) isomorph.  Thermal denaturation kinetics of hOGA revealed environmental factors 
affecting hOGA stability. From kinetics experiments, the synthesized compounds proved to 
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be efficient competitive inhibitors of hOGA with Ki-s in the range of ~30-250 nM and 
moderate selectivity with respect to lysosomal β-hexosaminidases. In silico studies consisting 
of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free 
energy calculations revealed the factors governing the observed potencies, and led to design 
of the most potent analogue 2-acetamido-2-deoxy-D-glucono-1,5-lactone 4-(2-naphthyl)-
semicarbazone 6g (Ki = 36 nM). The protocol employed has applications in future structure 
based inhibitor design targeting OGA.  
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O-GlcNAcylation has emerged as a major posttranslational modification (PTM) that 
indicates the energy, nutritional and stress status of the cell, and involves transfer of a single 
N-acetylglucosamine moiety from UDP-GlcNAc to a serine or threonine side chain of 
proteins [1]. The two most striking features of O-GlcNAcylation, which distinguish this PTM 
from N- and O-glycosylations are its localisation and its dynamic nature. It is localized to 
cytosol, nucleus and mitochondria rather than the endoplasmic reticulum or Golgi apparatus 
[2]. Similar to phosphorylation, two opposing enzyme actions determine the level of O-
GlcNAcylation of a protein: OGT (O-GlcNAc transferase), the transferase, which transfers 
the N-acetylglucosamine moiety and creates the β-glycosidic linkage between the protein and 
GlcNAc, and the hydrolase OGA (O-GlcNAcase), which cleaves the bond [3]. UDP-GlcNAc, 
produced by the hexosamine pathway, provides the GlcNAc moiety for OGT to transfer to the 
aliphatic hydroxyl groups of the proteins to be modified. This UDP-GlcNAc is the nutrient 
sensor of the cell and O-GlcNAcylation, in response to the hexosamine flux, modulates 
metabolism and affects numerous cellular processes such as transcription regulatory 
pathways, cell cycle progression, embryonic development, the regulation of the epigenome, 
respiration and proteosomal degradation [4-8]. O-GlcNAcylation does not only switch the 
biological function of key regulatory proteins on and off, but finely tunes their activities and 
interaction partners in the intracellular network. Imbalance in the GlcNAcylation cycle has 
been shown to manifest itself in diseases, where the hyperactivity of either OGA or OGT is 
observed. In nearly all cancers, an elevated level of O-GlcNAcylation was reported [9]. The 
trend is opposite in the brain, in multiple neurodegenerative diseases where decreased levels 
of O-GlcNAc modifications on numerous proteins have been reported, such as the proteins of 
the cytoskeleton [10]. The shift of homeostasis of O-GlcNAcylation to the increased 
hydrolysis of GlcNAc from the modified proteins is one of the main mechanisms contributing 
to neurodegeneration [11]. As a consequence of the complementary and competitive nature of 
phosphorylation and O-GlcNAcylation at many serine/threonine sites, low levels of O-
GlcNAcylation leads to hyperphosphorylation of cytoskeleton proteins in the brain, including 
the microtubule protein tau. The hyperphosphorylated form of tau has been found in 
neurofibrillary tangles, characterized as tauopathy. An increase of O-GlcNAcylation levels by 
inhibiting the activity of OGA has significantly decreased the aggregation propensity of tau 










GlcNAcylation, motivates biological studies, and design and synthesis of potent OGA 
inhibitors.  
Human OGA (hOGA) is a neutral hexosaminidase and belongs to family 84 of 
glycoside hydrolases (GH84) [14]. The enzyme follows a two-step substrate-assisted 
mechanism, through a dissociative oxocarbenium ion-like transition state, resulting in the net 
retention of the anomeric configuration [15]. This mechanism is shared by the acidic N-
acetylhexosaminidases, a member of GH20 [16]. In the GH84 family two neighbouring 
aspartates and in the GH20 enzymes, one aspartate and one glutamate, function as the key 
catalytic nucleophile and the acid/base residues [16-18]. There are specific human N-
acetylhexosaminidases that reside in lysosomes and are expressed in several tissues, mostly as 
a mixture of two isoenzymes: N-acetylhexosaminidase A (HexA) and N-
acetylhexosaminidase B (HexB) [19]. GH20 N-acetylhexosaminidases catalyse the hydrolysis 
of terminal, non-reducing N-acetyl-β-D-glucosamine and N-acetyl-β-D-galactosamine residues 
from proteoglycans [16, 20]. Both isoforms appear in plasma and in synovial fluid and 
become elevated in inflammatory processes. In the synovial fluid of patients with 
osteoarthritis, HexA and HexB are released by chondrocytes into the extracellular 
compartment, mainly responsible for the degradation of glycosaminoglycans (GAG) [21, 22]. 
Development of potent inhibitors against HexA and HexB are also highly relevant in studying 
the physiological role of these enzymes and their potential therapeutic applications. 
PUGNAc (Phenyl Urethane of GlcNAc, Chart 1) was one of the first inhibitors of 
OGA [23] with a Ki value of around 50 nM, however, it is not selective, since it inhibits 
GH20 N-acetylhexosaminidases in a similar manner. The N-phenylcarbamate moiety can 
form hydrogen bonds between the oxime nitrogen atom and catalytic site residues, and the 
phenyl moiety, which protrudes from the active site pocket, takes advantage of hydrophobic 
interactions with aromatic side chains [24]. 2-Acetamido-2-deoxy-D-gluconhydroximo-1,5-
lactone (LOGNAc), which lacks the phenyl carbamate group, is an around 30 times less 
potent inhibitor [23], showing that this moiety makes an important contribution to binding. 
Several other inhibitors are known in the literature, mostly transition state analogue 
compounds (NAG-thiazoline, NButGT, Thiamet-G), glucoimidazoles (GlcNacstatins) and 
non‐ carbohydrate‐ based inhibitors  have also been reported [25]. Surprisingly, there are 
only a few examples of PUGNAc analogues where the aromatic moiety is changed [26]. In 
addition, to the best of our knowledge, the effects of modifications of the urethane linker on 













Chart 1. The structure of some OGA inhibitors and the target compounds of this study. 
 
Though PUGNAc is a well established OGA inhibitor, its synthesis has some 
drawbacks. The first eight-step synthetic route [27] (overall yield: 14 %) included two critical 
steps: a) the incomplete and low yielding transformation of the starting compound in the 
oxidation step towards the hydroximo-1,5-lactone (50 % with 35 % unreacted starting 
material); b) a debenzylidenation with Na/NH3. The scale-up of both transformations to 
multigram synthesis led to lower yields and involved inconvenient workup procedures [28]. In 
an improved six-step synthesis [28] (overall yield: 15 %) the hydroximo-1,5-lactone was 
obtained in an 59 % yield only, and for this step keeping the -40°C temperature was crucial. 
At lower temperature the conversion was incomplete, while at higher temperature the 1,4-
lactone oxime was formed.  
With these preliminaries in mind we envisaged the synthesis of aryl substituted 
(thio)semicarbazones of 2-acetamido-2-deoxy-D-glucono-1,5-lactone (target compounds in 
Chart 1) whose preparation was expected to lack critical steps such as those for PUGNAc. 
Kinetics experiments were performed to determine the potencies for hOGA inhibition, as well 
as selectivity studies considering also N-acetylhexosaminidases. High level in silico 
calculations using quantum mechanics/molecular mechanics (QM/MM) methods were 
performed to understand the hOGA binding properties and relative inhibitory efficiencies of 
the compounds.  
 
Results and Discussion 
Synthesis 
A single representative of our target compounds (Chart 1, Ar = Ph, X = O) was located 
in the literature, therefore, the synthesis was based on the adaptation of this published 










glucopyranose (1) was obtained by a known two-step procedure [30, 31] from D-glucosamine 
hydrochloride. Compound 1 was then transformed by a 4-arylsemicarbazide (2, either 
commercial chemicals or obtained from the corresponding aromatic amines as described in 
the supporting material) in the presence of 10 mol% of p-toluenesulfonic acid as catalyst to 
get the N1-glycosyl semicarbazides 3. In place of the originally proposed 1,2-dichloroethane 
the use of dichloromethane, chloroform and toluene was tested for this transformation. In 
toluene the solubility of the starting material was insufficient, while the reaction in boiling 
CH2Cl2 resulted in lower yields than in CHCl3 at reflux temperature, therefore, the latter 
solvent was used in the reactions. With the semicarbazide derivatives 2a-g the equilibrating 
open-chain tautomers 4a-g were also observed in the 
1
H NMR spectra, while the reaction with 
thiosemicarbazide 2h was devoid of this product. No attempt was made to separate 
compounds 3 and 4. The NMR spectra of these mixtures contained signals which were 
analogous to those obtained for pure 3a and 4a in the literature [29]. The β(D) configuration 
of compounds 3 followed from the large 
 
3
JH-1 – H-2 couplings of 9-10 Hz (cf Experimental section). Oxidation of the mixtures 
containing 3 and 4 with CrO3-pyridine complex gave good yields of the expected lactone 
semicarbazones 5a-g. Regrettably, these oxidation conditions yielded complex reaction 
mixtures in case of the thio derivative 3h. Several oxidizing agents were tested (I2/NEt3, 
PIDA, ICl/Cs2CO3) and finally MnO2 proved to be efficient to furnish the required compound 
5h. The lactone semicarbazones 5 were O-deprotected by a solution of NH3 in MeOH to 
result in the test compounds 6. The overall yields of these five-step synthetic sequences to 























Reagents and conditions: a) 1. Ac2O, abs. Py, r.t.; 2. 4Å molecular sieves, abs. MeOH, r.t. (83 % for two 
steps) [30, 31]; b) NH2NHR (2), 0.1 equiv. pTsOH·H2O, CHCl3, reflux; c) with a-g: CrO3-Py, CH2Cl2, 0 
°C → r.t.; d) with h: MnO2, abs. CH2Cl2, reflux; e) NH3/MeOH, r.t.  
 
 R 
Products and yields (%) 
3 + 4 
Ratio
a
 of  
3 : 4 
5 6 
Overall yield of 6  
from D-glucosamine 
a CONHPh 90 5:1 83 79 49 
b CONH(p-MePh) 83 7:1 92 86 55 
c CONH(p-CF3Ph) 81 5:1 26 87 15 
d CONH(p-OMePh) 87 7:3 86 83 52 
e CONH(p-ClPh) 77 4:1 78 74 37 
f CONH(1-naphthyl) 94 
b 
64 83 41 
g CONH(2-naphthyl) 80 
b 
93 75 46 
h CSNHPh 87
c
 - 78 83 47 
a
 Determined from the 
1
H NMR spectra of the worked-up reaction mixtures. 
b
 Formation of the open-chain products 4f and 4g 
was detected by TLC but due to signal overlaps and small amounts of these compounds the 3 : 4 ratio was not established. 
c
 
Compound 3 formed as a single product. 
To verify the configuration of the C=N bond in compounds 6, a Nuclear Overhauser Effect 
(NOE) based NMR approach was applied to 6c (Figure 1). The E-Z isomeric forms of 
compounds 6 are expected to be distinguished on the basis of NOE cross-peaks between the 
N(2)H and distinctive protons of the sugar part, since the maximum spatial distance which can 














ROESY experiment [33] was performed, which is a powerful alternative of NOE 




H ROESY spectrum (Figure S2), the N(2)H 
resonance provided NOE cross-peaks with the H(5’) and O(6’)H resonances (Figure 1), which 
indicated the vicinity in space of these protons, and so, the presence of the Z isomeric form of 




C NMR spectra for the other compounds 6 closely 




Figure 1. Nuclear Overhauser Effects (NOEs) observed in compound 6c 
 
Heterologous expression of hOGA  
A heterologous expression system for hOGA in E. coli was established in order to gain 
soluble, active, full-length wild-type enzyme with considerable thermostability for the kinetic 
evaluation of the inhibitory potency of new inhibitors 6a-h against hOGA. Bacteriophage T7 
polymerase promoter based expression system such as BL21(DE3)/pET system was chosen 
for this purpose. The pET-28 based vector construct carrying the N-terminally His-tagged 
hOGA encoded gene was transformed into five E. coli BL21(DE3) strains and the cultivation 
conditions were optimised, as well as the environmental parameters of the downstream 
processes. The small scale expression trials of all the transformed BL21(DE3) strains carried 
out at 23 °C unravelled two main objectives to be solved in this expression system. Namely, 
the high tendency of the recombinant hOGA to form inclusion body aggregates during the 
protein production phase and the significant proteolytic degradation of the recombinant 
enzyme suffered in vivo and in vitro (Figure 2). We did experience the latter phenomenon, 
despite all the strains used were deficient in two proteases, an outer membrane protease 










responsible for degradation of misfolded proteins and interference with production of some 
full-length recombinant proteins [34-36]. In this respect, the worst performing strain was 
BL21(DE3), where full length recombinant enzyme was hardly produced (Figure 2). Beside 
the non-specific proteolysis, significant production of a 70 kDa long truncated hOGA 
fragment was observed with BL21 Star and pLysS strains referring to an existence of a 
sequence specific proteolytic cleavage site. This fragment bound to the affinity column and 
exhibited β-N-acetylglucosaminidase activity (see supporting material, Figure S3). The size 
and activity of this comparatively stable hOGA fragment suggests the presence of caspase-3-
like protease activity of E. coli cells that might be activated upon the overproduction of 
hOGA, causing a proteotoxic stress for the cell [37-40]. Two strains, RIPL and Rosetta, where 
the translation was optimized for genes that differ in codon usage from that of E. coli by 
carrying rare tRNA genes on plasmids, showed increased production of recombinant enzyme. 
However, only the Rosetta strain could increase the synthesis of the enzyme in the active, 
soluble form (Figure 2). The productivity of the Star and pLysS strains was very similar with 
a relatively high yield of active hOGA compared to the aggregate form. This highlights the 
importance of the increased life-time of mRNA in Star and the very tight control of 
expression in pLysS (Figure 2). However, Star and pLysS exhibited the highest site-specific 
proteolytic activity producing the 70 kDa long hOGA fragment. Table S1 summarizes the β-
N-acetylglucosaminidase activity of the cell lysates of the selected E. coli strain. It can be 
misleading to rely only on these results and rank the productivity of the strains according to 
these activity values. For instance, the BL21 (DE3) strain, which yielded the second highest 
β-N-acetylglucosaminidase activity, produced the lowest level of soluble, full-length 
recombinant enzyme. From all these observations it can be concluded that even though the 
strains have the same origin, they displayed different tolerance to the overproduction of 
misfolded protein, due to the activation of an extensive network of proteolytic housekeeping 











Figure 2. Gel electrophoretic (8% SDS-PAGE) analysis of the soluble and insoluble fractions 
of the cell lysates produced by different E. coli BL21(DE3) strains grown at 23 °C, induced at 
mid-exponential phase with 0.4mM IPTG and harvested at early stationary phase. 
Lanes 1. protein marker; 2. E. coli BL21(DE3) insoluble fraction; 3. E. coli BL21(DE3)  
soluble fraction; 4. E. coli BL21(DE3) RIPL insoluble fraction; 5. E. coli BL21(DE3) RIPL 
soluble fraction; 6. E. coli BL21(DE3) Rosetta insoluble fraction; 7. E. coli BL21(DE3) 
Rosetta soluble fraction; 8. E. coli BL21 Star (DE3) insoluble fraction; 9. E. coli BL21 Star 
(DE3) soluble fraction; 10. E. coli BL21(DE3) pLysS insoluble fraction; 11. E. coli 
BL21(DE3) pLysS soluble fraction 
 
Since the Rosetta strain proved to be the best performing expression host, systematic 
cultivation parameters were optimized for this strain. The effect of temperature on the 
recombinant protein production was investigated under 30 °C, at three temperatures (16, 23 
and 28 °C). The low protein concentrations in theory should decrease the partial folding and 
misfolding of proteins, thus, preventing the aggregation to inclusion body [43]. Decreasing 
the cultivation temperature only favoured full-length and active enzyme production at 23 °C. 
At lower temperature (16 °C), the misfolding of the human enzyme was accelerated and the 
chaperone systems of E. coli were not able to prevent the aggregate formation (see 
supplementary material, Figure S4, Table S2). 
The induction phase of the culture growth also influenced the yield of hOGA 
production. When the inducer was employed at later phase than the mid-exponential one (at 
OD600 0.9 instead of 0.6), we could achieve 50% higher yield (expressed in total β-N-










for the later phase induction in 250 ml cell culture) without compromising greater proteolytic 
degradation or formation of inclusion-body aggregates (Figure S5).  
All the optimized conditions were built in the final heterologous expression protocol 
for hOGA, in which aggregate formation of the overproduced enzyme was minimized and an 
efficient full-length, active hOGA production was ensured. 
 
Stability studies on wild-type hOGA 
The most important issue during the downstream processes was undoubtedly 
minimization of the action of E. coli proteases. Nevertheless, the identification of stabilizing 
and destabilizing factors involved in maintaining hOGA in its native state was also essential. 
Therefore, we carried out stability studies on hOGA by varying buffer compositions and we 
followed the heat-induced denaturation kinetics of the enzyme at 50 °C. The time-course of 
the enzyme residual activities was determined and the thermal denaturation kinetic constants 
(kD) or the half-lifes (t1/2) were calculated. By increasing the ionic strength, the thermal 
denaturation rate of the enzyme increased too, as was detected in phosphate buffer upon 
increasing KCl concentration (Figure S6a and Table S3). There was no significant difference 
in the rate of thermal denaturation of hOGA in the presence of either potassium or sodium 
cation (Figure S6b and Table S3). Treating hOGA solution with reducing agents such as 
mercaptoethanol and DTT proved to be an important protective factor increasing the protein 
half-life by up to 25% (Table S3 and Figure S7b). An even greater stabilizing effect was 
observed when phosphate buffer was supplemented with 15 % glycerol to increase the 
enzyme half-life by 80 % (Table S3). On the contrary, detergent Triton X-100 greatly 
destabilized hOGA native state and accelerated its thermal denaturation rate from kD= 0.05 to 
kD= 0.17 min
-1
, whereas the presence of Tween 20 proved to be an innocent factor in the 
structural disintegration of the enzyme (Figure S7a and Table S3). The effect of the majority 
of environmental factors on thermal denaturation kinetics of hOGA could be modelled by a 
single-transient process between the native and unfolded states that obeys a first-order 
kinetics. When phosphate buffer alone was present, the heat denaturation of hOGA followed 
sigmoidal kinetics, which applies for an autocatalytic process (indicating the autocatalytic 










suggested explanation for the existence of cooperativity in domain conformational changes is 
discussed in the supplementary material.  
We applied the stabilizing supplementations including the presence of reducing agent, 
Tween 20 and the preferable environmental factors such as low ionic strength, during the cell 
disruption process. It is also worth emphasizing the strict use of broad spectrum protease 
inhibitors during the cell lysis. During the affinity chromatography step, high salt 
concentration was necessary to avoid unspecific protein binding. The collected fractions of 
high β-N-acetylglucosaminidase activity were immediately ultrafiltrated to change the elution 
buffer into the ‘long storage buffer’ containing all the evaluated stabilizing supplementations 
including glycerol and kept at -20 °C. The concentration of the enzyme samples was not 
larger than 2 mg/ml. The single chromatographic purification step resulted in higher than 90 
% homogenous, full-length and active hOGA sample (Figure S8). Following the quality of the 
enzyme samples during the long time storage, their enzyme activity and homogeneity were 
maintained even after 12 months (Figure S8). 
 
Inhibitory potency of 2-acetamido-2-deoxy-D-glucono-1,5-lactone semicarbazone derivatives 
on hOGA and HexA/HexB activities 
Michaelis-Menten kinetic parameters for p-nitrophenyl-GlcNAc (pNP-GlcNAc) as 
substrate in the presence of hOGA established in potassium-phosphate buffer at pH 7.5 
resulted in 20 M for KM and 1.6 s
-1
 for kcat values (Table 2). The determined kcat value 
correlated well with the previously published data [44]. However, the enzyme in this study 
displayed much higher binding affinity toward pNP-GlcNAc than was previously reported for 
different conditions (Table 2). Kinetic analysis of hOGA and HexA/HexB inhibition by 2-
acetamido-2-deoxy-D-glucono-1,5-lactone semicarbazone derivatives was performed by using 
Dixon method [45] and an improved method presented by Cornish-Bowden [46] (Figure 3). 
Plotting the reciprocal initial rate against inhibitor concentration, the intersection point of the 
obtained curves at three different substrate concentrations was located in the fourth quadrant 
and gave the inhibitor constants (Ki) for all the investigated compounds (Table 3). The 
location of the intersection point also refers to the mode of inhibition, either competitive or 
mixed. Since Dixon plot cannot distinguish unambiguously between these inhibitory modes, 










lines are parallel in the plot of [S]/v against inhibitor concentration indicating competitive 
inhibition of hOGA and HexA/HexB enzymes by each of the 2-acetamido-2-deoxy-D-
glucono-1,5-lactone semicarbazone derivatives 6.  
 
Table 2. Michaelis-Menten kinetic parameters of hOGA for pNP-GlcNAc 
Buffer 
50 mM 
K2HPO4 - KH2PO4 
buffer, pH 7.5 
PBS 
(10 mM phosphate buffer, 
137 mM NaCl, 2.7 mM KCl)  
pH 7.4 [44] 
0.5 M 
citrate/phosphate buffer, 
pH 6.5 [47] 
KM 20 µM ± 2 170 µM ± 10 1.1 mM ± 0.1 
kcat (s
-1




Figure 3. Plotting hOGA inhibition data in the presence of 6a at three different pNP-GlcNAc 
concentrations (■ 75 M;  40 M; ▲ 20 M) by using Dixon method (A) and Cornish-
Bowden method (B). 
 
Inhibitor constants (Ki) for most of the compounds 6 against hOGA are in the 
submicromolar, in some cases in the nanomolar range, and slightly higher Ki values have been 
obtained for HexA/HexB (Table 3). The most potent inhibitors of hOGA are semicarbazones 










For the determination of the inhibitor constants of the most potent inhibitors (6e and 
6g), the Dixon method could not be used in the presence of the pNP-GlcNAc substrate 
because the inhibitor concentration was comparable to the enzyme concentration. Therefore, 
the fluorogenic 4-methylumbelliferyl-GlcNAc (4-MU-GlcNAc) substrate was used to enable 
the application of the more sensitive fluorometric detection method. This allowed a significant 
decrease in the applied enzyme concentration for the inhibition studies. In a separate 
experiment with 6f we demonstrated that substituting the chromogenic substrate (pNP-
GlcNAc) with a fluorogenic one (4-MU-GlcNAc) did not influence the binding affinity. The 
obtained Ki values for 6f in the presence of pNP-GlcNAc and 4-MU-GlcNAc were 0.506 ± 
0.020 M and 0.509 ± 0.036 M, respectively (Figure S9).  
The selectivity of inhibition of the two enzymes was moderate, and this feature 
resembles PUGNAc. It is worth noting the considerable difference in the inhibition by 
naphthyl derivatives 6f and 6g, of which the 2-naphthyl 6g is more than one order of 
magnitude more potent than the 1-naphthyl 6f counterpart. On the other hand, 6f is more 
selective towards HexA/HexB. 
Table 3. The binding affinities of 2-acetamido-2-deoxy-D-glucono-1,5-lactone semicarbazone 
derivatives toward hOGA and HexA/HexB enzymes (Ki [µM]) 
Compound hOGA HexA/HexB 
6a 
 
0.190 ± 0.008 
0.205 ± 0.014 
(lit.: 0.130 ± 0.020) [29] 
6b 
 
0.155 ± 0.003 0.332 ± 0.017 
6c 
 
0.167 ± 0.006 0.125 ± 0.004 
6d 
 














 0.170 ± 0.004 
6f 
 





 0.047± 0.002 
6h 
 
27 ± 3 30 ± 2 
‡  4-MU-GlcNAc was used as substrate 
 
 
In Silico Predictions Analysis  
In order to gain an understanding of the factors governing the observed potencies for 
hOGA inhibition, computations were performed in the form of Prime protein-ligand 
refinements [48], followed by higher level QM/MM optimizations and QM/MM-PBSA 
binding free energy calculations (ΔGbind, Eq. 1).  
ΔGbind = ΔEQM/MM + ΔGsolv – TΔSMM     Equation 1 
Eq. (1) includes contributions from gas-phase protein-ligand interaction energies 
(ΔEQM/MM), changes in solvation free energy on binding (ΔGsolv), as well as the ligand entropy 
changes (TΔSMM). In these calculations, side chains Tyr219, Phe223, Val254, Val255 and 
Tyr286 in the vicinity of 6a-g ligand phenyl or naphthyl rings were included as part of the 
QM region, selected due to the importance of these protein-ligand interactions to the observed 
potency differences, and to better describe π-π interactions with Tyr286. Because of the 
potential for a better description of binding site interactions using QM methods, QM/MM-










where protein-ligand π-π stacking interactions play a key role [50, 51]. Here, the QM region 
was modelled using DFT at the M06-2X/6-31+G** level of theory, with the M06-2X 
functional recognised for its description of non-covalent interactions [52-54]. We should note 
that native ligand docking calculations with Glide [48] failed to reproduce the PUGNAc 
ligand crystallographic conformation (PDB code: 5UHO); more specifically the critical 
orientation of the phenylurethane (-O-CO-NH-Ph) moiety, so that the Prime refinement, 
QM/MM optimization and QM/MM-PBSA approach as fully outlined in the experimental 
details was applied.   
The results of the QM-MM/PBSA calculations for PUGNAc and the eight inhibitors 
6a-h studied in this work are shown in Table 4. The final predicted ΔGbind values for each 
inhibitor are broken down into the different contributions from ΔEQM/MM, ΔGsolv, and TΔSMM. 
In terms of reproducing the relative potencies, good agreement with experiment was obtained 
(the absolute values of predicted ΔGbind are larger than experiment, an expected consequence 
of the method approximations [50, 51, 55]). PUGNAc was correctly predicted as more potent 
than the phenylsemicarbazone analogues 6a-e. PUGNAc and 6a differ structurally only in 
terms of their -O-C(O)-NH- and -NH-C(O)-NH- moieties, respectively. Compared to 
PUGNAc, 6a (and the other semicarbazone analogues, c.f. 6e complex in Figure 4 (A)) is able 
to exploit a hydrogen bond interaction from N2H (c.f. numbering scheme in Table 4) with the 
Tyr219 side chain hydroxyl O atom. While protein-ligand interactions based on ΔEQM/MM are 
predicted as stronger for 6a (-140.7 kcal/mol) compared to PUGNAc (-136.2 kcal/mol), the 
desolvation costs for 6a are greater, as well as entropy costs accounted for as loss of ligand 
vibration, rotation and translation on binding. Thiosemicarbazone 6h (a C=O to C=S 
replacement in the linker) was correctly predicted as the least potent ligand. Although its 
protein-ligand (ΔEQM/MM) interactions are predicted as strong (-145.9 kcal/mol), the 
desolvation cost of binding (119.0 kcal/mol) was the highest of all inhibitors in Table 4. 
 
Table 4. Quantum Mechanics ⁄ Molecular Mechanics – Poisson–Boltzmann Surface Area (QM ⁄ MM-
PBSA) results for the estimation of hOGA – ligand binding free energies using Eq. (1). The QM region 
was modelled at the M06-2X/6-31+G** level of theory; MM region using the OPLS-AA (2005) 
forcefield. All energy values are in kcal/mol. 










Ligand ΔEQM/MM ΔGsolv TΔSMM
a
 ΔGbind ΔGbind 
PUGNAc 
 
-136.2 96.2 -21.1 -18.9 -10.4 
6a 
 
-140.7 101.9 -21.8 -17.0 -9.5 
6b 
 
-143.1 103.3 -23.0 -16.8 -9.7 
6c 
 
 -152.7 111.8 -23.3 -17.6 -9.6 
6d 
 
-147.7 109.2 -22.9 -15.6 -9.3 
6e 
 
-148.4 107.8 -22.2 -18.4 -10.0 
6f 
 
-152.2 105.8 -23.0 -23.4 -8.9 
6g 
 












-145.9 119.0 -19.8 -7.1 -6.5 
a
 Values calculated at 310 K to be consistent with the performed kinetic experiments. Experimental ΔGbind 
= RT ln Ki. 
 
Analyzing the ΔGbind values for all the phenyl analogues 6a-e, compounds 6d and 6e 
are correctly predicted as the least and most potent inhibitors within this series, respectively; 
the remaining inhibitors in this series (6a-c) displayed similar experimental potencies (0.155-
0.190 µM) and had predicted potency ranks in between. Considering the electron donating or 
withdrawing properties of 6a-e para-substituents, there is no obvious correlation between 
these properties and the observed potencies. Indeed, considering the contributions to ΔGbind, 
the relative potencies of 6a-e are predicted to be a sensitive balance between protein-ligand 
interactions (ΔEQM/MM) and desolvation effects; entropy to a lesser degree. Given the good 
agreement between relative ΔGbind predicted and experimental values for the phenyl 
substituted compound series (Spearman rank correlation Rs = 0.893 (p < 0.01); Pearson 
correlation Rp = 0.993 (p < 0.01) – for PUGNAc, 6a-e and 6h), the predicted binding 
interactions could be analysed with confidence. 
The most potent phenyl analogue 6e has the strongest protein-ligand interactions 
(ΔEQM/MM = -148.4 kcal/mol), and its predicted protein-ligand complex is shown in Figure 4 
(A). The crystallographic N-acetyl-glucosamine moiety interactions in hOGA – PUGNAc 
(PDB code: 5UHO) are, as expected, conserved in the predicted complexes for the newly 
designed ligands 6a-h. These include key hydrogen bond interactions of inhibitor O4’ and 
O6’ hydroxyls (c.f. Table 4) with Asp285 side chain carboxylate; O4’-hydroxyl O with the 
Asn313 side chain amide; and O3’-hydroxyl with both Gly67 backbone O and Lys98 side 
chain. The N-acetyl group is involved in hydrogen bonds with Asp174 side chain carboxylate 
and Asn280 side chain amide. Considering the binding interactions of the phenyl substituents 
of 6a-6e (and 6h), there are favourable interactions with the hydrophobic side chains of 
Tyr219, Phe223, Val254, Val255 and Tyr286. Of particular significance are edge-to-face T-
shaped π-π stacking with Tyr286. Although the rings are not ideally aligned, the π-π stacking 










in Figure 4 (A)), close to theoretical optimum intermonomer distances (~4.8 – 5.0 Å) in 
simple model systems [56] and within the observed geometric preferences (5.0 – 5.6 Å) of 
protein – ligand (Phe – phenyl) T-shaped π-π interactions from Protein Data Bank analysis 
[57]. The protein-ligand ring planes had intersection angles 83.5° – 86.8°, that are also 
consistent with the T-stacking Protein Data Bank analysis [57]. Accounting for phenyl 
substituent effects for T-shaped configurations can be somewhat more complex than for 
sandwich arrangements [58]; in our situation (6a-e), the ligand π – π interactions with Tyr286, 
are accompanied by additional direct interactions between the ligand phenyl substituents and 











Figure 4. Predicted model complexes from Prime, QM/MM and QM/MM-PBSA 
calculations: (A) hOGA-6e and (B) hOGA-6g. 
 
Of further significance, we observed the potential for binding site loop Val255 
(backbone) NH – π interactions with the designed compounds. For the 6e complex (Figure 4 










3.8 Å. This analysis, in part, was the basis of our decision to explore naphthyl substituents 
that could better exploit such interactions (vide infra). Compound 6e, however, had the 
additional potential to form halogen Cl – hydrogen bond donor (HBD) interactions with 
Val255 NH. A quite recent QM study and survey of crystal structure data demonstrated that 
halogen (X) – HBD interactions can make significant contributions to ligand−protein binding 
[59]. Geometric parameters considered by the authors included the angle C–X–HBD and the 
distance HBD – X, with the HBD defined by its oxygen, nitrogen or sulfur atom. The survey 
revealed C–X–HBD angle maxima in the plots in the range ~ 80° to 110°. While the predicted 
C–X–HBD angle (66°) and HBD – X distance (4.9 Å) for the hOGA – 6e predicted model 
complex are also not optimum for halogen – HBD interactions, these interactions can occur 
over a broad range of angles and we must also consider that Val255 is part of a loop. 
Additionally, from the crystal structure data analysis, 60° – 70° angles for nitrogen as HBD 
were associated with mainly longer 4.0 – 4.5 Å distances. We can therefore postulate that the 
Val255 NH – Cl interaction may contribute to the improved potency of 6e compared to the 
other analogues 6a-6d.   
As mentioned, it was decided to explore whether substitution of the phenyls of 6a-6e 
with naphthyl moieties could better exploit potential NH – π contacts with Val255, but also 
the hydrophobic nature of other surrounding residues. Indeed, predictions for both 1- (6f) and 
2-naphthyl (6g) suggested improved potency, with predicted ΔGbind values of -23.4 and -24.3 
kcal/mol, respectively. And while the prediction was incorrect for 6f, potentially due to 
conformational entropy effects (over-prediction of 1-naphthalene compound analogues 
extends to other methods and systems [60]), 6g was experimentally the most potent of all 
ligands tested. The predicted binding of 6g with a 2-naphthyl moiety did as anticipated lead to 
better Val255 NH – π contacts (3.4 Å to centroid of ring extension), as well as preserving the 
edge-to-face T-shaped contacts with Tyr286 (Figure 4 (B)). The ΔEQM/MM value of -153.9 
kcal/mol was considerably more favourable (> 5 kcal/mol) to those obtained for the 
substituted phenyls. An alternative parallel conformation π-π binding mode with Tyr286 was 
also predicted for 6g, but was less favourable (ΔGbind = -11.4 kcal/mol) compared to the T-
shaped conformation (ΔGbind = -25.0 kcal/mol); in agreement, T-shaped binding 













A series of 2-acetamido-2-deoxy-D-glucono-1,5-lactone 4-aryl(thio)semicarbazone 
derivatives was obtained by a five-step synthetic sequence from D-glucosamine with overall 
yields of 15-55 %. These compounds represent the first analogues of PUGNAc with modified 
linkers between the sugar and the aromatic moiety. The reaction scheme offered a convenient 
synthetic route with the advantage of avoiding drawbacks encountered in the synthesis of 
PUGNAc. An efficient heterologous expression protocol for full length and active 
recombinant hOGA was developed by E. coli strain selection and optimization of cultivation 
conditions. This procedure minimized the misfolding of the overproduced enzyme, thereby 
reducing the proteotoxic stress, which was the cause of the strong proteolytic activity of the 
host. In this way, full-length and active recombinant enzyme was produced. Thermal 
denaturation studies revealed environmental factors that most affected hOGA stability, so that 
Applying the determined stabilization factors, hOGA samples displayed long-term stability 
and ensured reproducibility in the evaluation of inhibitory potencies. potency of the 
synthesized semicarbazone derivatives. Kinetic studies with hOGA and hexosaminidases A 
and B showed competitive inhibition for all synthesized semicarbazone derivatives 
compounds (hOGA: range of Ki-s ~30-250 nM; HexA/HexB: range of Ki-s ~50-400 nM) with 
a modest selectivity towards hOGA. These lactone semicarbazones are therefore alternatives 
of the long known OGA inhibitor PUGNAc in terms of both synthetic efficiency and 
inhibitory efficacy. A computational approach consisting of Prime protein-ligand refinements, 
post-processed by QM/MM optimizations and calculation of binding free energies using 
QM/MM-PBSA proved effective, for the most part, to describe the interactions governing the 
observed ligand potencies. This protocol has applications in future hOGA inhibitor design 
studies. The most potent inhibitor 6g (Ki = 36 nM) had a 2-naphthyl substituent that better 
exploited interactions (including NH – π and T-shaped π – π stacking), with surrounding 
hydrophobic residues. Halogen – HBD interaction seemed important for the second most 
potent ligand identified, 6e (Ki = 83 nM). Further computational and synthetic work to 














Melting points were measured on a Kofler hot-stage and are uncorrected. Optical 
rotations were determined with a Perkin–Elmer 241 or Jasco P-2000 (Easton, MD, USA) 
polarimeters at room temperature. NMR spectra were recorded by Bruker AM Avance 360 




C) spectrometer. Chemical shifts are referenced to TMS as the internal 
reference (
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C HMBC experiment [32] 




H EASY ROESY 
experiment [33] with 300 ms mixing time were performed on a Bruker Avance II 500 MHz 
spectrometer equipped with a 5 mm z-gradient TXI probe. Mass spectra were recorded with 
MicroTOF-Q type Qq-TOF MS and maXis II UHR ESI-QTOF MS (Bruker Daltonik, 
Bremen, Germany) instruments in positive ion mode with electrospray ionization or 
atmospheric pressure chemical ionization technique. TLC plates were visualized under UV 
light, and by spray reagent with gentle heating (the plate was sprayed with the following 
solution: abs. EtOH (95 ml), cc H2SO4 (5 ml), anisaldehyde (1 ml)). For column 
chromatography Kieselgel 60 (Merck, particle size (0.063–0.200 mm) was applied. 
Dichloromethane was distilled from P2O5 and stored over 4Å  molecular sieves. Pyridine was 
distilled from KOH and stored over KOH. CrO3 was stored over P2O5. 4-Phenylsemicarbazide 
(2a) and 4-phenylthiosemicarbazide (2h) were purchased from Sigma-Aldrich Ltd. (Budapest, 
Hungary). 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α,β-D-glucopyranose (1) [30, 31], 
substituted phenylsemicarbazides (2b-e) and 1- or 2- naphthylsemicarbazides (2f-g) [61] were 
synthesized according to literature procedures. Unless otherwise indicated, all chemicals used 
in the biochemical experiments were analytical-grade and purchased from Sigma-Aldrich Ltd. 
(Budapest, Hungary). 
 
General procedure I. for the synthesis of 1-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-
glucopyranosyl)-(thio)semicarbazides (3a-h)  
A solution of 200 mg (0.58 mmol) 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α,β-D-
glucopyranose (1), 0.87 mmol (thio)semicarbazide and 0.058 mmol p-toluenesulfonic acid in 
4 ml chloroform were boiled under reflux until the reactions were complete (monitored by 
TLC hexane : acetone = 3 : 2). The mixtures were cooled in ice-bath, the white precipitates 
were filtered. If the reagents contaminated the products, column chromatography was used 











General procedure II. for the synthesis of 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-D-
glucono-1,5-lactone semicarbazones (5a-h)  
 
Method A: A solution of 4 equivalents of anh. pyridine in 2 ml of anh. CH2Cl2 was stirred at 
25°C as 2 equivalents of dry CrO3 were added in one portion. The reaction was slightly 
exothermic, and the solution turned burgundy. After 20 min at 25°C, the solution was cooled 
to 0°C and a suspension of 100 mg compound in 3 ml of anh. CH2Cl2 was added in one 
portion. The reaction mixture was stirred, while it slowly warmed up to room temperature. 
After the reaction was complete (monitored by TLC hexane : acetone  1 : 1) it was diluted 
with 4 ml of Et2O. The mixture was filtered under vacuum and the filtrate concentrated. The 
pyridine was removed under high vacuum, and the residue was purified by column 
chromatography (hexane : acetone 2:1).   
 
Method B: Activated MnO2 was added to a solution of 100 mg compound in anh. CH2Cl2. 
The mixture was boiled until the reaction was complete (hexane : acetone 1:1), the MnO2 was 
filtered under vacuum and the filtrate concentrated, the residue was purified by column 
chromatography (hexane : acetone 2:1).   
 
General procedure III. for the synthesis of 2-acetamido-2-deoxy-D-glucono-1,5-lactone 
semicarbazones (6a-h)  
A solution of 100 mg compound in 1 ml of MeOH was stirred at 25°C with 1 ml of a 
sat. NH3/MeOH solution. After the reaction was complete (monitored by TLC, CHCl3 : 
MeOH 7:3) the solvent was removed and the residue was purified by column chromatography 
or was recrystallized (MeOH). 
 
Biochemical materials and methods 
Microorganisms and culture conditions 
Five different Escherichia coli strains were used for the expression of the long 
isomorph of hOGA: E. coli BL21(DE3), E. coli BL21(DE3) pLysS (from Novagen), E. coli 
BL21- CodonPlus (DE3)-RIPL (from Stratagene) and E. coli BL21 STAR(DE3) (from 
Invitrogen) and E. coli BL21(DE3) Rosetta. hOGA encoding gene was inserted between NdeI 
and XhoI restriction site of pET28b plasmid carrying kanamycin resistance. The resulting 










(Burnaby, Canada) [62]. The vector construct carrying hOGA encoding gene was transformed 
into the five E. coli strains by the heat-shock methods [63]. Resulting transformant cells of the 
different strains, were subjected to the protein expression procedure.  
 
Heterologous expression of human OGA in E. coli 
Small scale protein expression 
Small scale expressions were performed in 250 ml Luria broth (LB) growth medium 
supplemented with 50 μg/ml kanamycin antibiotics in 1L Erlenmeyer flasks and inoculated 
with 1 ml starter cultures of the different E. coli strains. They were grown overnight from a 
single colony, at 37 °C. The growing temperature of the small-scale expression was varied 
between 16-37 C, specifically 16 C, 23C and 28C. OGA enzyme was expressed by 
induction with 0.4 mM IPTG at about mid-log phase, OD600 ~0.6 or 0.9. Bacterial cells were 
harvested at stationary phase (OD600 ~ 1.4) by centrifugation at 6,000 rpm for 20 minutes at 
4C. The isolated pellet (~1.2-1.6 g) was kept at −20 °C for the later isolation procedures. The 
frozen pellet was re-suspended in 30 ml of lysis buffer (50 mM potassium-phosphate buffer, 
pH 7.5, containing 1mM DTT, 0.5 % Tween 20, Protease inhibitor cocktail (P8849, Sigma 
Aldrich, Hungary) and 0.1 mg/ml lysozyme) and kept on ice for 30 minutes. In addition to 
lysozyme, lysis was also performed by using an Ultrasonic Homogenizer UW 2070 (from 
Bandelin Electronic), at 4C. The resulting lysates were incubated with DNase in the presence 
of 1 mM MgCl2, for 120 minutes, at 10 C. Soluble fraction of the lysate was separated by 
centrifugation at 15,000 rpm, at 4 C and was kept at 4 C for the chromatographic separation 
which followed. During the expression and lysis, samples were collected for further 
characterization by gel electrophoresis, hexosaminidase activity testing and protein content 
determination, by the Bradford method, using BSA for the calibration curve [64].   
 
Large-scale protein expression 
Starter culture of E. coli Rosetta (DE3) strain was prepared (7x2 ml) to inoculate 500 
ml kanamycine (50 g/ml) supplemented LB medium in Erlenmeyer flasks (7x500 ml). The 
cells were grown at 23 C, until OD600 reached mid-log phase (~0.9), whereupon by adding 
0.4 mM IPTG the induction was carried out. The incubation of the growth was continued until 










at 4 °C. The collected pellet was weighed (~27 g) and kept frozen at -20 C. Lysis was carried 
out using the frozen sample by following the same procedure mentioned above (“small scale 
protein expression” section) except less lysis buffer was used to suspend the pellet in relation 
to “pellet mass/lysis volume” ratio (27 g pellet was dissolved in 400 ml lysis buffer). 
 
Chromatography of hOGA 
The long isomorph of hOGA protein was expressed as a fusion protein with an N-
terminal His-tag comprising of hexapeptide of histidine. HiPrep IMAC Fast Flow (diameter 
16mm, length 10mm; GE-Healthcare) column was charged up with Co
2+
 and pre-equilibrated 
with 20 mM potassium-phosphate buffer, pH=7.7, containing 0.5 M KCl, 50 mM imidazole 
and 0.5 % Tween 20 as binding buffer. The bound hOGA protein was eluted with a 50-500 
mM linear imidazole gradient in 20 mM potassium-phosphate buffer, pH=7.7, containing 0.5 
M KCl over 20 column volumes. The N-acetylglucosaminidase activity and the protein 
content of the fractions were determined. Those with the highest N-acetylglucosaminidase 
activity were pooled together and ultrafiltrated (Amicon Ultra – 100kDa, Merck Millipore) for 
a buffer exchange, into 50 mM potassium-phosphate buffer, pH=7.5 containing 1mM PMSF, 
1mM DTT, 1mM EDTA and 30% glycerol. The enzyme sample was stored at -20 °C in small 
aliquots.  
 
N-acetylglucosaminidase activity assay 
The N-acetylglucosaminidase activity of hOGA enzyme was determined using pNP-
GlcNAc substrate. Upon enzyme action, p-nitrophenol is liberated from the substrate in the 
enzyme-substrate reaction mixture. Quenching the enzyme effect by adding strong alkaline 
solution to the reaction mixture, the liberated p-nitrophenol product was detected by 
measuring the absorbance at 400 nm. For quantitative product estimation, the p-nitrophenol 
calibration curve was determined in a solution that contains one volume of the assay buffer 
and two volumes of the 0.2 M Na2HPO4/NaOH solution, pH = 12.0. N-acetylglucosaminidase 
activity determination was performed in 200 l of 50 mM potassium phosphate buffer, pH = 
7.5, containing 0.2 mM pNP-GlcNAc as a substrate, which was pre-incubated in 37 °C. The 
enzyme reaction was started by adding a 50 l hOGA sample to the above solution, 










adding 500 l of 0.2 M Na2HPO4/NaOH solution, pH = 12.0. The absorbance at 400 nm of 
the quenched reaction was followed and the enzyme activity was calculated in units of 
mol/min. 
 
Stability studies on hOGA 
Thermal stability of hOGA was measured by incubating the enzyme at 50 C in 
different solutions of varying the present cation and its concentration, the type of reducing 
agents, the type of detergents and their concentrations. In all cases, the stability studies were 
carried out by incubating 0.33 mg/ml hOGA at 50 C, and, at regular intervals (5 minutes for 
the first half hour, then every 10 minutes) samples (10 l) were taken and were placed on ice. 
For the incubation of hOGA samples, Thermalmixer MKR 13 (by HLC BioTech) was used by 
applying 200 rpm shaking. To the incubated samples, placed on ice, 40 l distilled water was 
added then the N-acetylglucosaminidase activity was measured by following the protocol 
described above. The sodium and potassium ion influence on the enzyme thermal stability 
was tested in 50 mM phosphate buffer, pH 7.5, containing 0.3 M KCl and 0.3 M NaCl. 
Thermal stability of hOGA in the presence of different reducing agents such as DTT (1 mM) 
and β-mercaptoethanol (1 mM) was also determined in 50 mM phosphate buffer, pH 7.5 as 
well as the effect of different detergents including 0.5 % Tween 20, 0.5 % Triton X-100 and 
glycerol in the same buffer. In all measurements the ratios of the N-acetylglucosaminidase 
activity determined at a given time interval (At) and at zero time (A0) were calculated as 
residual activities (At/A0). Residual activity was then plotted against time. The data points 
were fitted to a single step transition, from the native enzyme conformation to the denatured 
enzyme form (ENED), that followed first order kinetics: d[EN]/t = -kD[EN], where kD is the 
thermal denaturation rate (min
-1
). The active enzyme concentration ([EN]) is expressed as the 
residual enzyme activity (At/A0). Fitting residual activity vs incubation time according to the 
single exponential decay curve, lnAt/A0 will be constant and gives kD. For data fitting and 
graphic representation Origin-Pro-8 (OriginLab Corp. Northumpton, MA, USA) was used.  
Data points for residual activity versus time, giving sigmoidal curve, were modelled 
by using logistic equation (Eq. 2.): 
     
     
    (       ) 









where A1 is the bottom asymptote, A2 top asymptote, logxo center, p: slope factor that decides 
the steepness of the curve [65]. The logistic function is used for describing the rate of 
autocatalytic processes [66]. In this case y is residual activity, x is time, logxo the time needed 
for the denaturation of the half protein population (half-life).  
 
Residual activity versus time, which resulted in a biphasic sigmoid curve, can be fitted 
by biphasic logistic equation (Eq. 3.):  
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   Equation 3. 
where A1 is the bottom asymptote, A2 top asymptote, logxo1 centre of the first phase, logxo2 
centre of the second phase, h1 slope of the first phase, h2 slope of the second phase, p 
proportion between the phases. In this case, two-state transition was observed during the 
denaturation of the protein, the inflexion points (logxo1,   logxo2) of the biphasic sigmoid curve 




For determining the Michaelis-Menten constants of OGA for pNP-GlcNAc and 4-MU-
GlcNAc substrates, the enzymatic reactions were performed in 50 mM potassium phosphate 
buffer (pH 7.5) in a final volume of 1 ml, at 37 °C, containing varied final substrate 
concentrations. These ranged from 2 mM to 5 M (for both substrates) in the presence of two 
hOGA concentrations, namely 33 nM and 82 nM in case of pNP-GlcNAc and 3 nM in case of 
4-Mu-GlcNAc. Using pNP-GlcNAc substrate the reaction was conducted in 1 ml cuvettes 
held in the thermostated cell holder of AnalytikJena Specord 250 plus double beam 
spectrophotometer. On addition of the enzyme, the reactions were monitored continuously at 
400 nm. Using fluorogenic 4-MU-GlcNAc substrate, the reactions were set up in a 
fluorescence cuvette, held in thermostated cell holder of Jasco FP-8200 fluorescence 
spectrophotometer equipped with a Xe lamp light source at 37 °C. The reactions were 
initiated by the addition of 4-MU-GlcNAc and the liberated fluorescent product, 4-
methylumbelliferone, was followed with excitation at 360 nM, and emission was detected at 
450 nM every 10 seconds for 10 minutes. For determining the Michaelis-Menten constants of 
HexA/HexB for pNP-GlcNAc substrate, the enzymatic reactions were performed in 50 mM 










concentrations used ranged from 5 mM to 60 µM in the presence of 5.0 mU of HexA/HexB 
(from bovine kidney, Sigma Aldrich). Initial velocities were calculated within the linear 
region of the reaction progress curves obtained from using both the chromogenic and 
fluorogenic substrates, then Michaelis–Menten kinetic parameters were calculated through 
nonlinear regression of Michaelian saturation curves using Origin-Pro-8 (OriginLab Corp. 
Northumpton, MA, USA). Initial velocities were expressed in M of liberated product in one 
second as it was determined from the calibration curves of the liberated pNP. All the 
measurements were performed in triplicates. 
 
Inhibition studies 
All target compounds were evaluated for their inhibitory activities against hOGA and 
HexA/HexB. Inhibition studies were performed at three substrate concentrations (20 µM, 40 
µM and 75 µM for pNP-GlcNAc and 7.5 µM, 12.5 µM and 25 µM for 4-MU-GlcNAc) in a 
reaction mixture containing 50 mM potassium phosphate buffer (pH 7.5), final concentration 
of synthesized inhibitors (6a-g) ranging from 0 to 3 µM or from 0 to 200 µM for 6h, in the 
presence of 33 nM hOGA. In experiments using fluorogenic substrate, 3 nM hOGA was 
applied in the presence of 6e and 6g inhibitors, their concentrations ranged from 0 nM to 100 
nM. In case of HexA/HexB the pNP-GlcNAc concentrations were 0.5 mM, 1.0 mM and 1.5 
mM, except for 6e and 6h, where concentrations were 0.8 mM, 1.0 mM and 1.5 mM. The 
concentration of the inhibitors was in the 0 to 1 μM range, except for 6h where the range was 
from 0 to 50 μM. 
 
In all cases the enzyme and the inhibitors were pre-incubated at 37°C. The reactions 
were initiated by the addition of the substrate solution and the kinetic curves were recorded as 
described above. Initial velocities were estimated and the reciprocal of initial velocities 
plotted against inhibitor concentrations. All measurements were performed in triplicates. 
Inhibition constants (Ki) were determined by linear regression of data from Dixon plots [45]. 
The modality of the inhibition were assessed for the investigated compounds according to the 













hOGA was prepared for the initial Prime refinement calculations using Schrödinger’s 
Protein Preparation Wizard [48] and the solved 3.21 Å resolution co-crystallized complex of 
the protein (chains A-D) with PUGNAc (PDB code 5UHO). The waters within 5 Å of 
PUGNAc were initially retained (deleted for subsequent calculations), bond orders assigned 
and hydrogens added, with protonation states for basic and acidic residues based on calculated 
pKa’s at pH 7 from PROPKA [67]. Subsequent optimization of hydroxyls, histidine 
protonation states and C/N atom flips, as well as side chain O/N atom flips of Gln and Asn 
residues was based on optimizing hydrogen bonding patterns. The system was then minimised 
using OPLS-AA (2005) forcefield [68] with the RMSD (heavy atoms) maintained to within 
0.3 Å of the crystallographic positions. 
Prime Protein-Ligand Complex Refinements 
Initial models of protein-ligand complexes for each of the inhibitors 6a-h were 
prepared by mutation of the relevant atoms in the PUGNAc ligand in chain A of the prepared 
crystallographic hOGA-PUGNAc complex (PDB code: 5UHO; section 4.1.1). For the 
naphthyl analogues, rings were extended by fusing at both ortho-meta positions for 1-
napthalene and both meta-para positions for 2-napthalene. Prime v5.4 protein-ligand 
refinements [48] were then performed in local optimization mode for each new complex. 
Default settings were employed that included the OPLSe forcefield [69] and VSGB model of 
solvation [70]. Residues within 5 Å of PUGNAc in 5UHO were selected to be free in all 
refinements (same 360 atoms), with the rest of the protein atoms constrained. The method was 
also applied to the native PUGNAc ligand; comparing the Prime refined protein-ligand model 
with the crystal structure complex (following backbone superimposition), small RMSDs 
(heavy atoms) of 0.821 Å and 0.430 Å were obtained for ligand and flexible binding site 
residues, respectively. 
QM/MM and QM/MM-PBSA Calculations 
The Prime refined protein-ligand complexes for each ligand were used as input for 
QM/MM gas phase optimizations. In these calculations, the same protein residues were free 
and constrained as per the Prime refinements described above. The QM region consisted of 
the respective ligand and side chains of key binding site residues (Try219, Phe223, Val254, 
Val255 and Tyr286 of chain A) surrounding the phenyl/naphthyl ligand substituents, and was 










the rest of the systems were modelled using MM with the OPLS-AA(2005) forcefield [68]. 
For the QM with MM interface, hydrogen caps on the QM region residue side chains were 
used. No cut-off was used for non-bonded interactions. The MM region effectively polarizes 
the QM region, with interactions between QM and MM regions including electrostatic effects 
between the MM point charges and the QM wavefunction, as well as van der Waals terms 
between QM and MM atoms [73]. The optimized complexes were then used as input for 
single-point QM/MM-PBSA calculations [55], where the binding free energies (ΔGbind) were 
calculated as the difference in energies between the bound and the unbound states of the 
protein-ligand complexes using Eq. (1).  
ΔGbind = ΔEQM/MM + ΔGsolv – TΔSMM     Equation 1 
In Eq. (1), EQM/MM is the gas phase QM/MM energy; and Gsolv, the solvation free 
energy. For the latter, bulk solvation (water) effects were included using Poisson-Boltzmann 
Surface Area (PBSA) approach [74], with the default solute (internal) dielectric constant of 
1.0 used.  Otherwise, the QM and MM regions were modelled the same as for the preceding 
QM/MM optimizations.  The final term in Eq. (1) includes a MM estimate (OPLS-AA(2005) 
forcefield [68]) for the loss of ligand entropy (ΔSMM) on binding calculated using the Rigid 
Rotor Harmonic Oscillator (RRHO) approximation, which considers the vibrational, 
rotational and translational (VRT) entropy of the ligands; RRHO calculations were run using 
MacroModel v12.2 [48]. All QM/MM and QM/MM-PBSA calculations were performed 
using QSite (Jaguar v10.2; Impact v81012) [48]. Corrections for basis set superimposition 
error (BSSE) as a result of incomplete basis sets are not included with the Schrodinger 
qsite_binding_energies.py script used for QM/MM-PBSA calculations. However, it was 
important to probe the potential effects of neglect of BSSE on the predicted relative potencies 
(reported ΔGbind values). Accordingly, Jaguar v10.2 [48] gas phase QM calculations (M06-
2X/6-31+G**) on simplified model complexes of the inhibitors were performed using an 
approach previously described [50]. In these calculations the complexes consisted only of 
hydrogen capped side chains of residues from the QM region (Try219, Phe223, Val254, 
Val255 and Tyr286) and the ligands. Estimated BSSE effects calculated using the Boys-
Bernardi counterpoise (CP) method [75] revealed values ranging 2.5 – 3.0 kcal/mol and 
ΔEQM/MM values were corrected accordingly using the following equation [50]:   
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